Sponsors (26)
The bill greatly expands no‑cost HIV prevention access and outreach—especially for marginalized and uninsured populations—improving public health and equity, but does so at meaningful fiscal and administrative cost and introduces privacy, formulary, and litigation risks that policymakers will need to manage.
People covered by private group and individual plans, Medicaid/CHIP, Medicare, VA, and TRICARE will receive FDA‑approved HIV prevention drugs, related lab services, and follow‑up care with no patient cost‑sharing (and Medicare Part B deductibles/Part D cost‑sharing eliminated for relevant plan years), and preventive HIV services cannot be subject to prior authorization, improving timely access to,
Uninsured and underinsured people will gain direct access to PrEP/PEP through federally funded programs, navigators, adherence services, and supported service providers, lowering financial and access barriers for populations without coverage.
Communities disproportionately affected by HIV (including LGBTQ people, racial/ethnic minorities, tribal communities, and low‑income populations) will receive sustained outreach, public education, and clinician training funded through FY2026–FY2030, increasing PrEP/PEP awareness, provider offering, and uptake.
Taxpayers, federal and state budgets, and insurers will face substantial new costs because of expanded no‑cost coverage and authorized program funding, which could increase federal spending, strain state budgets, or lead insurers to raise premiums over time.
Health insurers, self‑funded plans, states, providers, and plan administrators will incur new administrative and compliance costs — e.g., annual reporting requirements, system changes to segregate confidential claims, Medicaid/CHIP plan modifications, grant administration, and provider training/reporting — which may be passed on to consumers or strain small providers.
Funding is authorized through FY2030 with 'such sums as may be necessary' and some program elements lack long‑term guarantees, creating uncertainty about sustainability and risking disruption of services if appropriations lapse after FY2030.
Based on analysis of 20 sections of legislative text.
Requires private plans to cover FDA‑approved PrEP/PEP and related services without cost‑sharing or routine prior authorization, funds education and grants, adds confidentiality and enforcement measures.
Introduced March 5, 2026 by Mark Takano · Last progress March 5, 2026
Requires private group and individual health plans to cover FDA‑approved HIV prevention drugs (PrEP and PEP) and related clinical services without cost‑sharing and generally without prior authorization. Directs HHS (with CDC, HRSA, and other agencies) to lead guidance, monitoring, enforcement, education campaigns, and a grant program to expand access for uninsured and underinsured people, strengthens confidentiality under HIPAA for people using these services, bars life/disability/long‑term care insurers from discriminating based on PrEP/PEP use, and creates a private right of action for enforcement. Plans and issuers must submit annual compliance data for 10 years; HHS and other agencies must report publicly and to Congress about noncompliance and program implementation on set timelines.